Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 801–900 of 1,078

1. Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
   Nune Markosyan, Jinyang Li, Yu Huining Sun, Lee P. Richman, Jeffrey H. Lin, Fangxue Yan, Liz Quinones, Yogev Sela, Taiji Yamazoe, Naomi Gordon et al. · 2019 · Journal of Clinical Investigation
2. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
   Petar Jelinic, Jacob M. Ricca, Elke Van Oudenhove, Narciso Olvera, Taha Merghoub, Douglas A. Levine, Dmitriy Zamarin · 2017 · JNCI Journal of the National Cancer Institute
3. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
   Jacob M. Hurst, Matthias Hoffmann, Matthew J. Pace, James P. Williams, John Patrick Thornhill, Elizabeth Hamlyn, Jodi Meyerowitz, Christian B. Willberg, Kersten K. Koelsch, Nicola Robinson et al. · 2015 · Nature Communications
4. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
   Valsamo Anagnostou, Mark M. Yarchoan, Aaron Richard Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah E. Collyar, Laura Q.M. Chow, Patrick M. Forde · 2017 · Clinical Cancer Research
5. Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically
   Shawn C. Chafe, Paul C. McDonald, Saeed Saberi, Oksana Nemirovsky, Geetha Venkateswaran, Samantha Burugu, Dongxia Gao, Alberto Delaidelli, Alastair Hugh Kyle, Jennifer H.E. Baker et al. · 2019 · Cancer Immunology Research
6. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion
   Lyndsay Avery, Jessica N. Filderman, Andrea L. Szymczak-Workman, Larry Kane · 2018 · Proceedings of the National Academy of Sciences
7. Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
   Chrisann Kyi, Michael Andrew Postow · 2016 · Immunotherapy
8. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
   Rebecca J. Lee, Gabriela Gremel, Andrea Marshall, Kevin A. Myers, Nita Fisher, Janet Dunn, Nathalie S. Dhomen, Pippa G. Corrie, Mark Ross Middleton, Paul C. Lorigan et al. · 2017 · Annals of Oncology
9. Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
   Amanda J. Oliver, Peter K. H. Lau, Ashleigh Unsworth, Sherene Loi, Phillip Kevin Darcy, Michael H. Kershaw, Clare Y. Slaney · 2018 · Frontiers in Immunology
10. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
    Khalil Choucair, Susan M. Morand, Laura Stanbery, Gerald M. Edelman, Lance D. Dworkin, John J. Nemunaitis · 2020 · Cancer Gene Therapy
11. Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches
    Paola Fisicaro, Valeria Barili, Marzia Rossi, Ilaria Montali, Andrea Lorenzo Vecchi, Greta Acerbi, Diletta Laccabue, Alessandra Zecca, Amalia Penna, Gabriele Missale et al. · 2020 · Frontiers in Immunology
12. Incidence and risk factors of drug‐induced liver injury
    Xiaoyun Li, Jie Ting Tang, Yimin Mao · 2022 · Liver International
13. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer · 2018 · Genome Medicine
14. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
    Wu, Xinqi, Giobbie-Hurder, Anita, Liao, Xiaoyun, Connelly, Courtney, Connolly, Erin M., Li, Jingjing, Manos, Michael P., Lawrence, Donald, McDermott, David, Severgnini, Mariano et al. · 2017 · Cancer Immunology Research
15. Biomarkers associated with checkpoint inhibitors
    Guillaume Manson, J. Norwood, Aurélien Marabelle, Holbrook E K Kohrt, Roch Houot · 2016 · Annals of Oncology
16. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
    Udupi Anantharamachar Ramagopal, Weifeng Liu, Sarah C. Garrett-Thomson, J.B. Bonanno, Qingrong Yan, Mohan Srinivasan, Susan C. Wong, Alasdair Bell, Shilpa Mankikar, Vangipuram S. Rangan et al. · 2017 · Proceedings of the National Academy of Sciences
17. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
    Muhammad Umair Mushtaq, Athanasios Papadas, Adam C. Pagenkopf, Evan Flietner, Zachary T. Morrow, Sibgha Gull Chaudhary, Fotis A. Asimakopoulos · 2018 · Journal for ImmunoTherapy of Cancer
18. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
    Omar Mohammed Abdel-Rahman, Hani Oweira, Ulf Petrausch, Daniel Helbling, Jan Schmidt, Meinrad Mannhart, Arianeb Mehrabi, Othmar Markus Schöb, Anwar Giryes · 2017 · Expert Review of Anticancer Therapy
19. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
    Chang Gong, Oleg Milberg, Bing Wang, Paolo Vicini, Rajesh Narwal, Lorin K. Roskos, Aleksander S. Popel · 2017 · Journal of The Royal Society Interface
20. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
    Curtis J. Perry, A. Muñoz-Rojas, K. Meeth, Laura N. Kellman, R. Amezquita, D. Thakral, Victor Y. Du, Jake X Wang, W. Damsky, Alexandra Kuhlmann et al. · 2018 · Journal of Experimental Medicine
21. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
    Hamzah Abu‐Sbeih, Tenglong Tang, Yang Lü, Selvi Thirumurthi, Mehmet Altan, Amir Anthony Jazaeri, Ramona Dadu, Emmanuel S. Coronel, Yinghong Wang · 2019 · Journal for ImmunoTherapy of Cancer
22. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
    Stefania Gori, Alessandro Inno, Lorenzo Belluomini, Paolo Bocus, Zeno Bisoffi, Antonio Dello Russo, Guido Arcaro · 2019 · Critical Reviews in Oncology/Hematology
23. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
    Yang Liu, Pan Zheng · 2019 · Trends in Pharmacological Sciences
24. TNF in the era of immune checkpoint inhibitors: friend or foe?
    Allen Y. Chen, Jedd D. Wolchok, Anne R. Bass · 2021 · Nature Reviews Rheumatology
25. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
    Yusuke Adachi, Hiroshi Kamiyama, Kenji Ichikawa, Sayo Fukushima, Yoichi Ozawa, Shogo Yamaguchi, Satoshi Goda, Takayuki Kimura, Kotaro Kodama, Masahiro Matsuki et al. · 2021 · Cancer Research
26. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
    Sirisha L. Mushti, Flora A. Mulkey, Rajeshwari Sridhara · 2018 · Clinical Cancer Research
27. Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
    Inês Pires da Silva, Serigne Lo, Camelia Y. J. Quek, Maria Gonzalez, Matteo Salvatore Carlino, Georgina Venetia Long, Alexander Maxwell Menzies · 2019 · Cancer
28. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non–small cell lung cancer (NSCLC)
    Ricciuti, Biagio, Jones, Greg, Severgnini, Mariano, Alessi, Joao V, Recondo, Gonzalo, Lawrence, Marissa, Forshew, Tim, Lydon, Christine, Nishino, Mizuki, Cheng, Michael et al. · 2021 · Journal for ImmunoTherapy of Cancer
29. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
    Lee, Hyunju, Hodi, F. Stephen, Giobbie-Hurder, Anita, Ott, Patrick A., Buchbinder, Elizabeth I., Haq, Rizwan, Tolaney, Sara, Barroso-Sousa, Romualdo, Zhang, Kevin, Donahue, Hilary et al. · 2017 · Cancer Immunology Research
30. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Benjamin Herzberg, Meghan J. Campo, Justin F. Gainor · 2016 · The Oncologist
31. Immune checkpoint inhibitor toxicities
    Marin-Acevedo, Julian A., Chirila, Razvan M., Dronca, Roxana S. · 2019 · Mayo Clinic Proceedings
32. Cardiovascular Toxicities Associated with Cancer Immunotherapies
    Daniel Y. Wang, Gosife Donald Okoye, Thomas Neilan, Douglas Buckner Johnson, Javid J. Moslehi · 2017 · Current Cardiology Reports
33. PD-1 and cancer: molecular mechanisms and polymorphisms
    Arash Salmaninejad, Vahid Khoramshahi, Alireza Azani, Ehsan Soltaninejad, Saeed Aslani, Mohammad Reza Zamani, Masoud Zal, Abolfazl Nesaei, Sayed Mostafa Hosseini · 2017 · Immunogenetics
34. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
    Karim Boudadi, Daniel L. Suzman, Valsamo Anagnostou, Wei Fu, Brandon S. Luber, Hao Wang, Noushin Niknafs, James Robert White, John L. Silberstein, Rana Sullivan et al. · 2018 · Oncotarget
35. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
    Qiang Su, Emily C. Zhu, Jingbo Wu, Teng Li, Yanli Hou, Diya Wang, Zu‐Hua Gao · 2019 · Frontiers in Immunology
36. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
    Qingzhu Jia, Jun Wang, Ning He, Ji He, Bo Zhu · 2019 · JCI Insight
37. Advances in immunotherapy for melanoma
    Jason Mark Redman, Geoffrey Thomas Gibney, Michael B. Atkins · 2016 · BMC Medicine
38. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
    Andrew Bang, Tyler J. Wilhite, Luke Pike, Daniel N. Cagney, Ayal Aaron Aizer, Allison Taylor, Alexander Spektor, Monica Shalini Krishnan, Patrick Alexander Ott, Tracy Anne Balboni et al. · 2017 · International Journal of Radiation Oncology*Biology*Physics
39. Review article: systemic treatment of hepatocellular carcinoma
    Matthias Pinter, Markus Peck‐Radosavljevic · 2018 · Alimentary Pharmacology & Therapeutics
40. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
    Mbofung, Rina M., McKenzie, Jodi A., Malu, Shruti, Zhang, Min, Peng, Weiyi, Liu, Chengwen, Kuiatse, Isere, Tieu, Trang, Williams, Leila, Devi, Seram et al. · 2017 · Nature Communications
41. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
    Kimbara, Shiro, Fujiwara, Yutaka, Iwama, Shintaro, Ohashi, Ken, Kuchiba, Aya, Arima, Hiroshi, Yamazaki, Naoya, Kitano, Shigehisa, Yamamoto, Noboru, Ohe, Yuichiro · 2018 · Cancer Science
42. PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
    Joel Chaim Sunshine, Peter L. Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Jessica Esandrio, Haiying Xu, Aleksandra Ogurtsova, Karen B. Bleich, Toby C. Cornish et al. · 2017 · Clinical Cancer Research
43. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
    Katrin Aslan, Verena Turco, Jens Blobner, Jana K. Sonner, Anna Rita Liuzzi, Nicolás Gonzalo Núñez, Donatella De Feo, Philipp Kickingereder, Manuel Dominik Fischer, Ed Green et al. · 2020 · Nature Communications
44. Applications of single-cell and bulk RNA sequencing in onco-immunology
    Maria Kuksin, Daphné Morel, Marine Aglave, François‐Xavier Danlos, Aurélien Marabelle, Andrei Y. Zinovyev, Daniel Gautheret, Loïc Verlingue · 2021 · European Journal of Cancer
45. Cancer immunologists scoop medicine Nobel prize
    Heidi K. Ledford, Holly Else, Matthew Warren · 2018 · Nature
46. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone
    Kristian Michael Koller, Heath B. Mackley, Jason Liu, Henry Wagner, Giampaolo Talamo, Todd D. Schell, Colette Pameijer, Rogerio Izar Neves, Bryan E. Anderson, Kathleen M. Kokolus et al. · 2016 · Cancer Biology & Therapy
47. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
    Xianda Zhao, Subbaya Subramanian · 2017 · Cancer Research
48. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
    Alexander Noor Shoushtari, Claire Frances Friedman, Pedram Navid-Azarbaijani, Michael Andrew Postow, Margaret K. Callahan, Parisa Momtaz, Katherine S. Panageas, Jedd D. Wolchok, Paul B. Chapman · 2017 · JAMA Oncology
49. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
    Juliya Fisher, Nathalie C. Zeitouni, Weijia Fan, Faramarz H. Samie · 2019 · Journal of the American Academy of Dermatology
50. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
    Sceneay, Jaclyn, Goreczny, Gregory J., Wilson, Kristin, Morrow, Sara, DeCristo, Molly J., Ubellacker, Jessalyn M., Qin, Yuanbo, Laszewski, Tyler, Stover, Daniel G., Barrera, Victor et al. · 2019 · Cancer Discovery
51. Immune checkpoint inhibition in ovarian cancer
    Junzo Hamanishi, Masaki Mandai, Ikuo Konishi · 2016 · International Immunology
52. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
    Julia Reinhardt, Jennifer Landsberg, Jonathan Leo Schmid-Burgk, Bartomeu Bibiloni Ramis, Tobias Bald, Nicole Glodde, Dorys Lopez-Ramos, Arabella Young, Shin Foong Ngiow, Daniel Nettersheim et al. · 2017 · Cancer Research
53. Neurologic complications of immune checkpoint inhibitors
    Avi Fellner, Chen Makranz, Michal Lotem, Felix Bokstein, Alisa Taliansky, Shai Rosenberg, Deborah T. Blumenthal, Jacob Joseph Mandel, Suzana Fichman, Elena Kogan et al. · 2018 · Journal of Neuro-Oncology
54. Cutaneous Melanoma—A Review in Detection, Staging, and Management
    Rebecca Ivy Hartman, Jennifer Y. Lin · 2018 · Hematology/Oncology Clinics of North America
55. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
    Hari Menon, Rishab Ramapriyan, Taylor R. Cushman, Vivek Verma, Hans H. Kim, Jonathan E. Schoenhals, Semra Cemre Atalar, Uğur Selek, Stephen G. Chun, Joe Yujiao Chang et al. · 2019 · Frontiers in Immunology
56. Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
    Adam M. Hirst, Fiona M. Frame, Manit Arya, Norman J. Maitland, Deborah O’Connell · 2016 · Tumor Biology
57. Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
    Monica Khunger, Adrián Vladimir Hernández, Vinay Pasupuleti, Sagar Rakshit, Nathan A. Pennell, James P. Stevenson, Sanjay Mukhopadhyay, Kurt Alex Schalper, Vamsidhar Velcheti · 2017 · JCO Precision Oncology
58. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
    Jun Ishihara, Kazuto Fukunaga, Ako Ishihara, Hans M. Larsson, Lambert Potin, Peyman Hosseinchi, Gabriele Galliverti, Melody A. Swartz, Jeffrey A. Hubbell · 2017 · Science Translational Medicine
59. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
    Markus W. Loeffler, Christopher Mohr, Leon Bichmann, Lena Katharina Freudenmann, Mathias Walzer, Christopher Schroeder, Nico Trautwein, Franz J. Hilke, Raphael S. Zinser, Lena Mühlenbruch et al. · 2019 · Genome Medicine
60. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
    Georgina Venetia Long, Jason J. Luke, Muhammad Adnan Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood et al. · 2022 · The Lancet Oncology
61. Checkpoint inhibitors in breast cancer – Current status
    Anne Dyhl-Polk, Inge Marie Svane, Michael Andersson, Dorte Lisbet Nielsen · 2017 · Cancer Treatment Reviews
62. Synthetic lethality-mediated precision oncology via the tumor transcriptome
    Joo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, Lesley M. Chapman, Youngmin Chung, Kun Wang, Sanju Sinha, Hongui Cha, Dasol Kim, Alexander V. Schperberg et al. · 2021 · Cell
63. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
    Thiem, Alexander, Hesbacher, Sonja, Kneitz, Hermann, di Primio, Teresa, Heppt, Markus V., Hermanns, Heike M., Goebeler, Matthias, Meierjohann, Svenja, Houben, Roland, Schrama, David · 2019 · Journal of Experimental & Clinical Cancer Research
64. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
    Simpson, Rebecca C., Shanahan, Erin R., Scolyer, Richard A., Long, Georgina V. · 2023 · Nature Reviews Clinical Oncology
65. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
    Marcel A. Deken, Jules Gadiot, Ekaterina S. Jordanova, Ruben Lacroix, Melissa M. J. van Gool, Paula Kroon, Cristina Pineda, Marnix H. Geukes Foppen, Richard A. Scolyer, Ji‐Ying Song et al. · 2016 · OncoImmunology
66. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
    Lironne Wein, Sherene Loi · 2017 · The Breast
67. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
    Michael Collins, Jean‐Marie Michot, F.X. Danlos, Charlotte Mussini, Émilie Soularue, Christine Mateus, Delphine Loirat, Anthony Buisson, Isabelle Rosa, Olivier Lambotte et al. · 2017 · Annals of Oncology
68. Immunotherapy for osteosarcoma: Where do we go from here?
    Mary Frances Wedekind, Lars M. Wagner, Timothy P. Cripe · 2018 · Pediatric Blood & Cancer
69. Mast Cells: A New Frontier for Cancer Immunotherapy
    Jake N. Lichterman, Sangeetha Meda Reddy · 2021 · Cells
70. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance
    Orgaz, Jose L., Crosas-Molist, Eva, Sadok, Amine, Perdrix-Rosell, Anna, Maiques, Oscar, Rodriguez-Hernandez, Irene, Monger, Jo, Mele, Silvia, Georgouli, Mirella, Bridgeman, Victoria et al. · 2020 · Cancer Cell
71. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
    Elizabeth Liniker, Alexander Maxwell Menzies, Benjamin Y. Kong, Adam James Cooper, Sangeetha Ramanujam, Serigne Lo, Richard F. Kefford, Gerald Blaise Fogarty, Alexander David Guminski, Wei Wang et al. · 2016 · OncoImmunology
72. Targeting immune checkpoints in breast cancer: an update of early results
    Cinzia Solinas, Andrea Gombos, Sofiya Latifyan, Martine J Piccart, Marleen Kok, Laurence Buisseret · 2017 · ESMO Open
73. The Influence of Tumor Microenvironment on Immune Escape of Melanoma
    Aleksandra Simiczyjew, Ewelina Dratkiewicz, Justyna Mazurkiewicz, Marcin Ziętek, Rafał Matkowski, Dorota Nowak · 2020 · International Journal of Molecular Sciences
74. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
    Neeraj Chhabra, Joseph M. Kennedy · 2021 · Journal of Medical Toxicology
75. Cardiotoxicity of Immune Checkpoint Inhibitors
    Rushin P. Patel, Rohan B. Parikh, Krishna Soujanya Gunturu, Rana Zouveenoor Tariq, Sourbha S. Dani, Sarju Ganatra, Anju Nohria · 2021 · Current Oncology Reports
76. Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
    Bailey, Christopher M., Liu, Yan, Liu, Mingyue, Du, Xuexiang, Devenport, Martin, Zheng, Pan, Liu, Yang, Wang, Yin · 2022 · Journal of Clinical Investigation
77. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
    Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen et al. · 2017 · Clinical Cancer Research
78. Anti–CTLA-4 therapy requires an Fc domain for efficacy
    Jessica R. Ingram, Olga S. Blomberg, Mohammad Rashidian, Lestat R. Ali, S. Garforth, E.V. Fedorov, Alexander A. Fedorov, J.B. Bonanno, Camille M. Le Gall, Stephanie J. Crowley et al. · 2018 · Proceedings of the National Academy of Sciences
79. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics
    Xiao Han, Hongjun Li, Daojia R. Zhou, Zhaowei Chen, Zhen Gu · 2020 · Accounts of Chemical Research
80. The gut microbiome: what the oncologist ought to know
    Karla A. Lee, Marilan Luong, Heather May Shaw, Paul Nathan, Veronique A. Bataille, Tim D. Spector · 2021 · British Journal of Cancer
81. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
    Charu Aggarwal, Amy Prawira, Scott Joseph Antonia, Osama E. Rahma, Anthony W. Tolcher, Roger B. Cohen, Yanyan Lou, Ralph J. Hauke, Nicholas J. Vogelzang, Dan Paul Zandberg et al. · 2022 · Journal for ImmunoTherapy of Cancer
82. Melanoma central nervous system metastases: current approaches, challenges, and opportunities
    Justine Vanessa Cohen, Hussain Tawbi, Kim Allyson Margolin, Ravi Amravadi, Marcus Bosenberg, Priscilla Kaliopi Brastianos, Veronica Chiang, John de Groot, Isabella C. Glitza, Meenhard Herlyn et al. · 2016 · Pigment Cell & Melanoma Research
83. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
    Roberta Mazzone, Clemens Zwergel, Antonello Mai, Sérgio Valente · 2017 · Clinical Epigenetics
84. Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer
    Ya Gao, Shuzhen Shi, Wenjuan Ma, Ji Chen, Yitong Cai, Long Ge, Lun Li, Jiarui Wu, Jinhui Tian · 2019 · International Immunopharmacology
85. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
    James W. Opzoomer, Dominika Sosnowska, Joanne E. Anstee, James F. Spicer, James N. Arnold · 2019 · Frontiers in Immunology
86. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
    Frank Friedrich Gellrich, Marc Schmitz, Stefan Beissert, Friedegund Elke Meier · 2020 · Journal of Clinical Medicine
87. Immune checkpoint inhibitors in cancer therapy
    S. Eika, Liu Peng, Renato B. Baleeiro, R. Nicholas, Yuan Ming, Wang Yaohe · 2017 · Journal of Biomedical Research
88. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
    Elizabeth Iannotti Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna Pradyuman Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer Fishman, Rene C. Gonzalez, Joseph I. Clark et al. · 2019 · Journal for ImmunoTherapy of Cancer
89. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
    Mengwei Zhang, Jinkai Liu, Qiang Xia · 2023 · Experimental Hematology and Oncology
90. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino, Gerardo Botti, Paul C. Lorigan, Giuseppe Valentino Masucci, Jason Hipp, Christine E. Horak, Ignacio Melero, Paolo A. Ascierto · 2016 · Drugs
91. Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies
    Jonathan Rios‐Doria, Jay W. Harper, Raymond P. Rothstein, Leslie K. Wetzel, Jon W. Chesebrough, Allison M. Marrero, Cui Chen, Patrick Strout, Kathy A. Mulgrew, Kelly McGlinchey et al. · 2017 · Cancer Research
92. Tumor infiltrating lymphocytes in early breast cancer
    Giancarlo Pruneri, Andrea Vingiani, Carsten Denkert · 2017 · The Breast
93. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses
    Xiang Liu, Zujian Feng, Changrong Wang, Qi Su, Huijuan Song, Chuangnian Zhang, Pingsheng Huang, Xing‐Jie Liang, Anjie Dong, Deling Kong et al. · 2019 · Biomaterials
94. Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4
    Lisa A. Marshall, Sachie Marubayashi, Aparna Jorapur, Scott Jacobson, Mikhail Zibinsky, Omar Robles, Dennis X. Hu, Jeffrey J. Jackson, Deepa Pookot, Jerick Sanchez et al. · 2020 · Journal for ImmunoTherapy of Cancer
95. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
    Yelena Yuriy Janjigian, Eric Van Cutsem, Kei Muro, Zev A. Wainberg, Salah‐Eddin Al‐Batran, Woo Jin Hyung, Daniela Molena, Michelle Marcovitz, Dario Ruscica, Scott H. Robbins et al. · 2022 · Future Oncology
96. Armed oncolytic viruses: A kick-start for anti-tumor immunity
    J. Fréderique de Graaf, Lisanne de Vor, Ron A. M. Fouchier, Bernadette G. van den Hoogen · 2018 · Cytokine & Growth Factor Reviews
97. Cancer Immunotherapy: Beyond Checkpoint Blockade
    Michael Lawrence Dougan, Glenn Dranoff, Stephanie K. Dougan · 2018 · Annual Review of Cancer Biology
98. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
    Andrew P. Georgiadis, Jennifer N. Durham, Laurel A. Keefer, Bjarne R. Bartlett, Magdalena Zielonka, Derek M. Murphy, James Robert White, Steve Lu, Ellen L. Verner, Finey Ruan et al. · 2019 · Clinical Cancer Research
99. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
    Italia Falcone, Fabiana Conciatori, Chiara Bazzichetto, Gianluigi Ferretti, Francesco Cognetti, Ludovica Ciuffreda, Michèle Milella · 2020 · Cancers
100. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis of published data
     Wenjun Wang, Puyi Lie, Minzhang Guo, Jianxing He · 2017 · International Journal of Cancer